RxDoctor Payments Data

Jose Acevedo, MD

General Practice · Arecibo, PRNPI 1336170950

Payments from drug & device makers

$454in general payments, 2019–2025

Across 30 payments — averaging $15.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$317
  • Boehringer Ingelheim$36
  • Bayer Puerto Rico Inc.$24
  • Johnson & Johnson$23
  • Boston Scientific$16
  • E.r. Squibb & Sons, L.L.C.$15
  • plus $23 from 2 others

What the payments were for

  • Food & beverage$454100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca21$317
Boehringer Ingelheim3$36
Bayer Puerto Rico Inc.1$24
Johnson & Johnson1$23
Boston Scientific1$16
E.r. Squibb & Sons, L.L.C.1$15
PBG Puerto Rico LLC1$11
Pfizer Pharmaceuticals LLC1$11

How this compares

$454 in reported general payments places this provider in the 70th percentile of 3,586 general practice providers in Puerto Rico.

See all general practice providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$8,522
Medicare patients
18
Services billed
115

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol93$115,861
SynthroidLevothyroxine Sodium574$66,782
EliquisApixaban52$62,077
LantusInsulin Glargine,hum.Rec.Anlog118$33,845
SantylCollagenase Clostridium Hist.21$31,896
Spiriva RespimatTiotropium Bromide26$30,364
JanumetSitagliptin Phos/Metformin Hcl31$28,343
TradjentaLinagliptin23$26,543
MounjaroTirzepatide22$23,782
Breo ElliptaFluticasone/Vilanterol38$21,518
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate44$20,120
XareltoRivaroxaban14$19,361
Stiolto RespimatTiotropium Br/Olodaterol Hcl14$19,339
Lagevrio (Eua)Molnupiravir27$18,289
JanuviaSitagliptin Phosphate12$18,136

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Brilinta$317$121,295104 claims
Boehringer IngelheimSpiriva Respimat, Tradjenta, Stiolto Respimat, Synjardy, Trijardy Xr$36$96,44195 claims
Johnson & JohnsonXarelto$23$19,36114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,586 general practice providers in Puerto Rico.

Other general practice in Arecibo

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →